Log inSign up
Ekta Batra
6,671 posts
Ekta Batra profile banner
@ekta_batra

Ekta Batra

@ekta_batra
Editor, Pharmaceutical and Health, CNBC TV18. Reporting, Analysing Pharma & Health since 2008. Tweets personal. Coffee & puppy addict. Myopic bt not in my views
Mumbai
moneycontrol.com/elite/profile/…
Joined April 2009
744
Following
71.4K
Followers
RepliesRepliesRepostsRepostsMediaMedia

Log in or sign up for X

See what’s happening and join the conversation

Continue with phone
or
Log in with username or email
Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
  • Pinned
    @ekta_batra
    Ekta Batra
    @ekta_batra
    Apr 30, 2022
    What a week. 2nd award in a week! Been awarded the Best continuing coverage by a reporter at the ENBA Broadcast awards. Bronze. Couldn't have done it without the fabulous team @cnbctv18india ❤️
    111
  • @ekta_batra
    Ekta Batra
    @ekta_batra
    8h
    CIPLA SIGNS ONCOLOGY DEAL W/ CHINA’S SINO BIOPHARM 🇨🇳💊 • Gets exclusive rights to Cancer drug TQB2102 • Rights cover India South Africa + 5 EMs • Drug shows potential in HER2-low breast cancer • Cipla to handle lcommercialisation • Sino's arm CTTQ to manf drug @CNBCTV18Live
  • @ekta_batra
    Ekta Batra
    @ekta_batra
    8h
    SUN PHARMA SIGNS US DEAL 🇺🇸💊 • Agrees to extend MFN pricing to US Medicaid • Commits to MFN pricing for future innovative meds • Section 232 tariffs on innovative drugs delayed for 2+ years • US accounts for ~27% ofglobal revenue *MFN: Most Favored Nation @CNBCTV18Live
  • @ekta_batra
    Ekta Batra
    @ekta_batra
    Aug 17
    MOLBIO DIAGNOSTICS Sees a strong listing Innovation driven co, large dependence on TB Truenat breast & cervical cancer could be a large mrkt 60% of pathology market is US Got USFDA approval 6 weeks ago for a product No M&A plans as of nw @CNBCTV18Live
    2
  • @ekta_batra
    Ekta Batra
    @ekta_batra
    Aug 15
    No Revlimid generic in their portfolio this quarter
    @CNBCTV18News
    CNBC-TV18
    @CNBCTV18News
    Aug 14
    #1QWithCNBCTV18 | Natco Pharma Profit Skids 57% In Q1 * Net profit declines 57% YoY to Rs 206.5 crore * EBITDA margin contracts to 25.4% from 43% * International formulations revenue falls to Rs 477 crore from Rs 1,120 crore @ekta_batra #NatcoPharma #Pharma #Healthcare
    00:00